AstraZeneca to pay $5.52 mln to resolve U.S. SEC foreign bribery case
August 30, 2016 at 18:29 PM EDT
NEW YORK, Aug 30 (Reuters) - U.S. regulators said on Tuesday that AstraZeneca Plc will pay $5.52 million to resolve a foreign bribery probe into improper payments by its sales and marketing staff to officials at state-controlled health care providers in China and Russia.